Imunon, Inc. Payments to Acquire Debt Securities, Available-for-sale
Imunon, Inc. (IMNN) reported Payments to Acquire Debt Securities, Available-for-sale of $57.17 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-03-31
- Imunon, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Imunon, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Imunon, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-06-30 was -$48.77K, a 140.79% decline year-over-year.
- Imunon, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2024-03-31 was $105.95K, a 97.00% decline year-over-year.
- Imunon, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $57.17K, a 99.58% decline from fiscal 2023.
- Imunon, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $13.54M, a 71.92% decline from fiscal 2022.
- Imunon, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $48.23M, a 10.38% decline from fiscal 2021.
- Imunon, Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $53.81M, a 440.44% increase from fiscal 2020.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 3 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 9 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | -$48.77K derived: sum of 3 quarters · filed 2026-03-31 | $57.17K 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$48.77K derived: sum of 2 quarters · filed 2025-11-13 | $57.17K 10-Q · filed 2025-11-13 | $9.86M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$48.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $57.17K 10-Q · filed 2025-08-05 | $9.86M derived: sum of 3 quarters · filed 2025-08-05 | $9.95M derived: sum of 4 quarters · filed 2025-08-05 | ||||
| 2024-03-31 | $105.95K 10-Q · filed 2025-05-12 | $9.91M derived: sum of 2 quarters · filed 2025-05-12 | $10.00M derived: sum of 3 quarters · filed 2025-05-12 | $10.12M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $9.90M derived: sum of 2 quarters · filed 2025-02-27 | $10.02M derived: sum of 3 quarters · filed 2025-02-27 | $13.54M 10-K · filed 2025-02-27 | ||||
| 2023-09-30 | $91.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $211.53K derived: sum of 2 quarters · filed 2024-11-07 | $3.74M 10-Q · filed 2024-11-07 | $43.58M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $119.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $3.65M 10-Q · filed 2024-08-14 | $3.65M 10-Q · filed 2023-08-10 | $43.49M derived: sum of 3 quarters · filed 2024-08-14 | $43.53M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $3.53M 10-Q · filed 2024-05-13 | $3.42M 10-Q · filed 2023-05-11 | $43.37M derived: sum of 2 quarters · filed 2024-05-13 | $43.41M derived: sum of 3 quarters · filed 2024-05-13 | $48.79M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $39.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $39.88M derived: sum of 2 quarters · filed 2024-03-28 | $45.26M derived: sum of 3 quarters · filed 2024-03-28 | $48.23M 10-K · filed 2024-03-28 | $48.19M 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $42.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $5.42M derived: sum of 2 quarters · filed 2023-11-14 | $8.39M 10-Q · filed 2023-11-14 | $8.40M 10-Q · filed 2022-11-14 | $21.34M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $5.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $8.34M 10-Q · filed 2023-08-10 | $8.41M 10-Q · filed 2022-08-15 | $21.29M derived: sum of 3 quarters · filed 2023-08-10 | $21.23M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $2.97M 10-Q · filed 2023-05-11 | $15.92M derived: sum of 2 quarters · filed 2023-05-11 | $15.85M derived: sum of 3 quarters · filed 2023-05-11 | $41.78M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $12.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $12.88M derived: sum of 2 quarters · filed 2023-03-30 | $38.81M derived: sum of 3 quarters · filed 2023-03-30 | $53.81M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | -$64.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $25.86M derived: sum of 2 quarters · filed 2022-11-14 | $40.86M 10-Q · filed 2022-11-14 | $40.86M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $25.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $40.93M 10-Q · filed 2022-08-15 | $40.93M derived: sum of 3 quarters · filed 2022-08-15 | $40.94M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $15.00M 10-Q · filed 2022-05-16 | $15.00M derived: sum of 2 quarters · filed 2022-05-16 | $15.01M derived: sum of 3 quarters · filed 2022-05-16 | $15.01M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $16.00K derived: sum of 2 quarters · filed 2022-03-31 | $16.36K derived: sum of 3 quarters · filed 2022-03-31 | $9.96M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $16.36K derived: sum of 2 quarters · filed 2021-11-15 | $9.96M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $360.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $9.94M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $9.94M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |